spacer
home > ebr > summer 2003 > giving vaccines the boost they need
PUBLICATIONS
European Biopharmaceutical Review

Giving Vaccines the Boost They Need

Estimated revenues for therapeutic biologics are set to grow to $50 billion per annum, with immunotherapeutics predicted to grow to 10 per cent of the prescription drug market ($40 billion) within the next decade. Creating immunotherapeutics for diseases such as cancer however, represents a significant challenge for the industry. For example cancer vaccines have to overcome 'self tolerance', the immune system's in-built reluctance to attack its own cells.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Deirdre Gillespie, President and Chief Executive Officer at Oxxon PharmaccinesTM Ltd

Dr Deirdre Gillespie is President and Chief Executive Officer of Oxxon PharmaccinesTM Ltd, a biotechnology company developing innovative immunotherapeutics, specifically therapeutic vaccines (pharmaccines), for the treatment of chronic infectious diseases and cancer. While at Oxxon, Deirdre has overseen the progression of the company's pharmaccines for the treatment of Hepatitis B and malignant melanoma into Phase II clinical trials.

Deirdre was also instrumental in a recently announced private financing that saw Oxxon raise £15 million in an international funding round. She has 16 years' experience in the pharmaceutical and biotechnology industries including senior positions at Vical Inc and DuPont Merck Pharmaceutical Company. Deirdre gained a medical degree from London University and an MBA from London Business School.

spacer
Dr Deirdre Gillespie
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

3P Biopharmaceuticals and Nordic Nanovector have extended partnership for Betalutin® late stage manufacturing for B-cell non-Hodgkin lymphoma (NHL) treatment

The non-Hodgkin lymphoma (NHL) is a cancer that starts in white blood cells called lymphocytes, which are part of the body’s immune system
More info >>

White Papers

Another Successful Visit Against the Odds

Medical Research Network (MRN) Limited

Our dedicated team of nurses, couriers and project managers deliver, come rain or shine. Making sure a Clinical Trial visit can go ahead in the home can be a complex process, and last month bad weather nearly stopped play on an important Home Trial Support visit. Thanks to the commitment and dedication from the entire team it went ahead against the odds.
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement